On Saturday 22nd at EuroThrombosis & EuroVessels 2022 in Lisbon, Dr. Sem A.O.F. Rikken presented:
‘Zalunfiban (RUC-4) and Pre-procedural Patency of the Infarct-related Artery in ST-Elevation Myocardial Infarction; insights from the Phase IIa study. Oral Abstract No 53, Cardiovascular Research 2022 Volume 118, Supplement 2, 22 Oct 2022.’
Results and Conclusions:
- In a Phase IIa study, zalunfiban showed prompt, potent, dose-dependent, short-during platelet inhibition
- In an exploratory post-hoc analysis, zalunfiban in the two higher doses showed (statistically significant)
– Greater patency (TIMI flow grade 2-3) of IRA compared to the lower dose
– Greater microvascular perfusion (TIMI myocardial perfusion grade 3) pre-PCI compared of the IRA compared to the lower dose
– Lower thrombus burden (TIMI thrombus grade ≥4) compared in the IRA to the lower dose - Zalunfiban is currently investigated in the phase III double-blinded, randomized, placebo-controlled, CELEBRATE trial (NCT04825743)
Authors
Sem A.O.F. Rikken, MD; Willem L. Bor, MD; Kai L. Zheng, MD; C. Michael Gibson, MD M; Christopher B. Granger, MD; Ohad Bentur, MD; Rita Lobatto, MD; Sonja Postma, PhD; Barry S. Coller, MD PhD; Arnoud W.J. van ’t Hof, MD PhD; Jurrien M. ten Berg MD PhD